منابع مشابه
Imatinib mesylate induced skin hypopigmentation.
Sir, Imatinib mesylate is a tyrosine kinase inhibitor that targets BCR-ABL protein in chronic myelogenous leukemia (CML).1 We present three cases of CML, treated with Imatinib who developed clinical findings of hypopigmentation. All the three patients noticed pigmentation changes after the initiation of therapy with Imatinib mesylate, which was persistent during therapy. The presence of hypopig...
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملImatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
532 Ann Dermatol Received January 7, 2013, Revised July 3, 2013, Accepted for publication July 29, 2013 Corresponding author: Hee Young Kang, Department of Dermatology, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-gu, Suwon 443-380, Korea. Tel: 82-31-219-5190, Fax: 82-31-2195189, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creat...
متن کاملImatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
AIMS Coxsackievirus B3 (CVB3)-induced chronic myocarditis in mice is accompanied by severe fibrosis and by sustained elevation of platelet-derived growth factor (PDGF)-A, -B, and -C levels in the cardiac tissue. To test if PDGF stimulation of resident fibroblasts causally contributes to fibrosis, we employed inhibition of PDGF receptor signalling with the orally available kinase inhibitor Imati...
متن کاملImatinib mesylate: A designer drug.
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Dermatology, Venereology, and Leprology
سال: 2012
ISSN: 0378-6323
DOI: 10.4103/0378-6323.95491